Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is
predominantly influenced by disease type and status, it is essential to be able to stratify …

The outcome of allogeneic HSCT varies considerably by the disease and remission status at
the time of transplantation. Any retrospective or prospective HSCT study that enrolls patients …

We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …

Cure of malignant and non-malignant hematological diseases is potentially possible after
allogeneic hematopoietic stem cell transplantation (HCT). Accurate evaluation of the risk …

Clinical decisions in allogeneic hematopoietic stem cell transplantation (allo-HSCT) are
supported by the use of prognostic scores for outcome prediction. Scores vary in their …

BACKGROUND: It was investigated whether the European Group for Blood and Marrow
Transplantation risk score, previously established for chronic myeloid leukemia, could be …

Prospective validation of the hematopoietic cell transplantation–comorbidity index (HCT-CI)
using contemporary patients treated with hematopoietic cell transplantation (HCT) across …

The development of tools for the prediction of nonrelapse mortality (NRM) after allogeneic
hematopoietic stem cell transplantation (HSCT) would offer a major guidance in the …

The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was developed
at a single center to predict outcomes for allogeneic transplant recipients who have …

Background: Despite recent advances, mortality rates after allogeneic hematopoietic cell
transplantation remain high and cannot be accurately predicted. Objective: To develop a …